Study Number:	C13115-01
Study Sex:	Male
PWG Approval Date:	See web page for date of PWG Approval
Version:	v1.7.6
Stat Version:	2023.02.27S

Study Number: C13115-01
Test Type: TOX
Route: Oral Gavage
Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: 3-(2H-Benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid, octyl ester
CAS Number: 84268-23-5

Date Report Requested: 04/24/2026
Time Report Requested: 11:08:22
Lab: Battelle

Male

		Treatment Groups (mg/kg)				
	Phase Day	**0**	**30**	**100**	**300**	**1000**
Urea Nitrogen (mg/dL)	SD 14	15.0 ± 0.6 (5) **	16.8 ± 0.7 (5)	17.4 ± 1.0 (5)	22.8 ± 1.0 (5) **	70.0 ± 23.6 (3) **
Percent of Control			112.0	116.0	152.0	466.7
Creatinine (mg/dL)	SD 14	0.40 ± 0.00 (5)	0.36 ± 0.02 (5)	0.34 ± 0.02 (5)	0.36 ± 0.02 (5)	0.83 ± 0.27 (3)
Percent of Control			90.0	85.0	90.0	208.3
Glucose (mg/dL)	SD 14	153.2 ± 17.0 (5) *	149.0 ± 10.0 (5)	132.6 ± 5.4 (5)	131.6 ± 3.4 (5)	122.3 ± 9.5 (3)
Percent of Control			97.3	86.6	85.9	79.9
Total Protein (g/dL)	SD 14	6.78 ± 0.18 (5) **	6.58 ± 0.07 (5)	6.36 ± 0.18 (5)	6.26 ± 0.05 (5) *	5.70 ± 0.40 (3) *
Percent of Control			97.1	93.8	92.3	84.1
Globulin (g/dL)	SD 14	2.42 ± 0.08 (5) **	1.66 ± 0.02 (5) *	1.54 ± 0.05 (5) *	1.52 ± 0.06 (5) *	1.73 ± 0.20 (3) *
Percent of Control			68.6	63.6	62.8	71.6
A/G Ratio	SD 14	1.81 ± 0.05 (5)	2.97 ± 0.08 (5) *	3.14 ± 0.13 (5) **	3.14 ± 0.15 (5) **	2.32 ± 0.15 (3)
Percent of Control			164.3	173.9	173.9	128.7
Albumin (g/dL)	SD 14	4.36 ± 0.12 (5)	4.92 ± 0.08 (5) *	4.82 ± 0.17 (5)	4.74 ± 0.07 (5)	3.97 ± 0.20 (3)
Percent of Control			112.8	110.6	108.7	91.0
Cholesterol (mg/dL)	SD 14	110.6 ± 5.1 (5)	94.2 ± 3.4 (5)	85.6 ± 6.6 (5)	85.6 ± 4.3 (5)	165.3 ± 24.4 (3)
Percent of Control			85.2	77.4	77.4	149.5
Triglyceride (mg/dL)	SD 14	100.0 ± 13.9 (5)	70.0 ± 9.5 (5)	61.2 ± 4.1 (5)	66.8 ± 1.9 (5)	99.7 ± 9.9 (3)
Percent of Control			70.0	61.2	66.8	99.7
Alanine Aminotransferase (IU/L)	SD 14	67.4 ± 11.9 (5) **	60.4 ± 4.7 (5)	82.8 ± 5.2 (5)	82.2 ± 7.1 (5)	115.7 ± 7.3 (3) **
Percent of Control			89.6	122.8	122.0	171.6
Alkaline Phosphatase (IU/L)	SD 14	196.8 ± 22.4 (5) **	234.4 ± 12.7 (5)	432.0 ± 22.6 (5) **	447.8 ± 29.8 (5) **	940.3 ± 118.6 (3) **
Percent of Control			119.1	219.5	227.5	477.8

Study Number: C13115-01
Test Type: TOX
Route: Oral Gavage
Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: 3-(2H-Benzotriazol-2-yl)-5-(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid, octyl ester
CAS Number: 84268-23-5

Date Report Requested: 04/24/2026
Time Report Requested: 11:08:22
Lab: Battelle

Male

		Treatment Groups (mg/kg)				
	Phase Day	**0**	**30**	**100**	**300**	**1000**
Creatine Kinase (IU/L)	SD 14	219.4 ± 29.5 (5)	154.6 ± 20.0 (5)	183.6 ± 18.4 (5)	221.6 ± 42.4 (5)	179.3 ± 19.1 (3)
Percent of Control			70.5	83.7	101.0	81.7
Sorbitol Dehydrogenase (IU/L)	SD 14	9.5 ± 1.3 (5)	7.1 ± 0.2 (5)	8.4 ± 0.5 (5)	7.2 ± 0.7 (4)	9.7 (1)
Percent of Control			74.4	88.2	75.9	101.9
Bile salt/acids (µmol/L)	SD 14	16.4 ± 5.6 (5) **	44.2 ± 6.1 (5) *	79.2 ± 14.3 (5) **	47.0 ± 5.9 (5) **	94.0 ± 12.7 (3) **
Percent of Control			269.5	482.9	286.6	573.2

LEGEND

Values given as mean ± SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100

SD = Study Day

Statistical analysis was performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Data with sample size of 1 in the treatment group were included in trend test, but excluded from the multiple comparisons tests.

Statistical significance for the control group indicates a significant trend test.

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group.

* Statistically significant at p <= 0.05

** Statistically significant at p <= 0.01

SEM = Standard Error of the Mean

Clinical chemistry data not reported was removed as an outlier, or was due to pre-analytical or analytical conditions or errors including but not limited to: below linearity, short sample, quantity not sufficient, or extreme hemolysis.

** END OF REPORT **